Department of Endocrinology and Diabetology, The Children's Memorial Health Institute, Warsaw, Poland.
Department of Oncology, The Children's Memorial Health Institute, Warsaw, Poland.
Front Endocrinol (Lausanne). 2022 May 20;13:868558. doi: 10.3389/fendo.2022.868558. eCollection 2022.
Pituitary stalk thickening (PST) is a rare abnormality in the pediatric population. Its etiology is heterogeneous. The aim of the study was to identify important clinical, radiological and endocrinological manifestations of patients with PST and follow the course of the disease.
It is a study conducted in 23 patients (13 boys) with PST with/without central diabetes insipidus (CDI) diagnosed between 1990 and 2020 at Children's Memorial Health Institute (CMHI) in Warsaw, Poland. We analyzed demographic data, clinical signs and symptoms, radiological findings, tumor markers, hormonal results, treatment protocols and outcomes.
The median age at the diagnosis of PST was 9.68 years (IQR: 7.21-12.33). The median time from the onset of the symptoms to the diagnosis was 2.17 years (IQR: 1.12-3.54). The most common initially reported manifestations were polydipsia, polyuria and nocturia (82.6%); most of the patients (56.5%) also presented decreased growth velocity. Hormonal evaluation at the onset of PST revealed: CDI (91.3%), growth hormone deficiency (GHD) (56.5%), hyperprolactinemia (39%), central hypothyroidism (34.8%), adrenal insufficiency (9%), precocious puberty (8.7%). The majority of the patients were diagnosed with germinoma (seventeen patients - 73.9%, one of them with teratoma and germinoma). Langerhans cell histiocytosis (LCH) was identified in three patients (multisystem LCH in two patients, and unifocal LCH in one patient). A single case of atypical teratoid rhabdoid tumor, suspected low-grade glioma (LGG) and lymphocytic infundibuloneurohypophysitis (LINH). The overall survival rate during the observational period was 87.0%.
The pituitary infundibulum presents a diagnostic imaging challenge because of its small size and protean spectrum of disease processes. Germinoma should be suspected in all children with PST, especially with CDI, even when neurological and ophthalmological symptoms are absent.
垂体柄增粗(PST)是儿科人群中罕见的异常。其病因具有异质性。本研究旨在确定伴有或不伴有中枢性尿崩症(CDI)的 PST 患者的重要临床、放射学和内分泌表现,并随访疾病过程。
这是一项在波兰华沙儿童纪念健康研究所(CMHI)于 1990 年至 2020 年期间诊断的 23 例(13 名男孩)伴有/不伴有 CDI 的 PST 患者的研究。我们分析了人口统计学数据、临床症状和体征、影像学发现、肿瘤标志物、激素结果、治疗方案和结局。
PST 的中位诊断年龄为 9.68 岁(IQR:7.21-12.33)。从症状出现到诊断的中位时间为 2.17 年(IQR:1.12-3.54)。最初报告的最常见表现为多饮、多尿和夜尿(82.6%);大多数患者(56.5%)也表现出生长速度减慢。PST 发病时的激素评估显示:CDI(91.3%)、生长激素缺乏症(GHD)(56.5%)、高泌乳素血症(39%)、中枢性甲状腺功能减退症(34.8%)、肾上腺皮质功能不全(9%)、性早熟(8.7%)。大多数患者被诊断为生殖细胞瘤(17 例患者-73.9%,其中 1 例为畸胎瘤和生殖细胞瘤)。Langerhans 细胞组织细胞增生症(LCH)在 3 例患者中被发现(2 例为多系统 LCH,1 例为局灶性 LCH)。1 例不典型畸胎样横纹肌样瘤、疑似低级别胶质瘤(LGG)和淋巴细胞漏斗神经垂体炎(LINH)。观察期间的总生存率为 87.0%。
由于垂体柄体积小且疾病过程多样,因此其影像学表现具有诊断挑战性。所有伴有 PST 的儿童,尤其是伴有 CDI 的儿童,即使没有神经和眼科症状,也应怀疑为生殖细胞瘤。